Immunic (NASDAQ:IMUX) Downgraded to Sell Rating by StockNews.com

StockNews.com lowered shares of Immunic (NASDAQ:IMUX) from a hold rating to a sell rating in a research note issued to investors on Monday.

IMUX has been the topic of a number of other reports. D. Boral Capital reissued a “buy” rating and set a $17.00 price target on shares of Immunic in a report on Tuesday, January 7th. HC Wainwright initiated coverage on shares of Immunic in a research report on Monday, November 25th. They issued a “buy” rating and a $10.00 price objective for the company. One analyst has rated the stock with a sell rating, six have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $12.67.

Immunic Trading Down 1.3 %

Shares of NASDAQ:IMUX opened at $0.94 on Monday. The company has a market capitalization of $84.50 million, a PE ratio of -0.76 and a beta of 1.87. Immunic has a 12-month low of $0.92 and a 12-month high of $2.11. The business has a 50 day moving average of $1.05 and a two-hundred day moving average of $1.27.

Hedge Funds Weigh In On Immunic

Large investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC purchased a new stake in shares of Immunic during the third quarter worth about $50,000. HB Wealth Management LLC acquired a new stake in Immunic in the 4th quarter worth about $81,000. Jane Street Group LLC boosted its holdings in Immunic by 121.4% in the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock worth $116,000 after buying an additional 38,553 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its stake in Immunic by 70.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock worth $169,000 after buying an additional 42,383 shares in the last quarter. Finally, State Street Corp raised its holdings in shares of Immunic by 7.5% during the third quarter. State Street Corp now owns 167,145 shares of the company’s stock valued at $276,000 after acquiring an additional 11,642 shares during the last quarter. 51.82% of the stock is currently owned by institutional investors and hedge funds.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.